Press release
Natera to Present New Data at the 2025 ASCO GI Symposium
First set of abstracts released include Signatera™ data from BESPOKE CRC, the largest prospective, observational, multicenter MRD study in the U.S. to date,
About this update from Natera, Inc.
[{"type":"text","content":"\nFirst set of abstracts released include Signatera™ data from BESPOKE CRC, the largest prospective, observational, multicenter MRD study in the U.S. to date, along with the first read-outs in early cancer detection and tissue-free MRD\n\n\nAdditional Signatera data will be shared at ASCO GI on Jan. 25, 2025, including a late-breaking oral presentation on the CALGB (Alliance) / SWOG 80702 study\n\n\n AUSTIN, Texas--(BUSINESS WIRE)--\nNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the first set of abstracts have been released from several studies that will be shared at the American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI) taking place Jan. 23 – 25, 2025 in San Francisco, CA.\n\n\nBESPOKE CRC Study\n\n\nNew data will be presented in an oral presentation on Jan. 25 from BESPOKE CRC, a multicenter, prospective, observational study in colorectal cancer (CRC). The study underscores Signatera’s capability as a prognostic and a predictive biomarker in a cohort of over 1,000 patients wherein post-surgical Signatera-positivity was predictive of inferior outcomes in stage II patients [disease-free survival (DFS) (HR=10.4; p","length":1928,"tagName":"div"}]